Results 21 to 30 of about 21,169 (256)
European Journal of Hybrid Imaging, 2022 Background Magnetic resonance imaging (MRI) is recommended by the European Urology Association guidelines as the standard modality for imaging-guided biopsy.
Daniela A. Ferraro +13 more
doaj +1 more source
Prostate‐specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma
The Prostate, 2023 AbstractIntroductionProstate‐specific membrane antigen (PSMA) is a US Food and Drug Administration‐approved theranostic target for prostate cancer (PCa). Although PSMA is known to be glycosylated, the composition and functional roles of its N‐linked glycoforms have not been fully characterized.MethodsPSMA was isolated from pooled seminal plasma from ...
Stephen Mackay +5 more
openaire +2 more sources
Application of PSMA PET/CT Specific Molecular Imaging in Diagnosis of Non-prostate Cancer
Zhongliu Fangzhi Yanjiu, 2019 Prostate specific membrane antigen(PSMA) is a glutamate carboxypeptidase Ⅱ secreted by the epithelial cells of prostate gland. PSMA is over-expressed in the cells of prostate cancer and metastases, and also positively expressed in the tumor-related ...
LIU Teli +5 more
doaj +1 more source
World Journal of Nuclear Medicine, 2020 Prostate-specific membrane antigen (PSMA)-targeted imaging is now an effective tool for the evaluation of prostate cancer patients. Although salivary glands take up 68Ga-PSMA avidly, pathologies of these glands may be readily noticeable.
Abbas Yousefi-Koma +4 more
doaj +1 more source
Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. [PDF]
, 2017 BackgroundPET/MRI can be used for the detection of disease in biochemical recurrence (BCR) patients imaged with 68Ga-PSMA-11 PET. This study was designed to determine the optimal MRI sequences to localize positive findings on 68Ga-PSMA-11 PET of patients
Behr, Spencer C +7 more
core +1 more source
World Journal of Nuclear Medicine, 2020 Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein which is extremely overexpressed in prostate cancer epithelial cells. Recently, PSMA-targeted small molecule labeled with 68Ga and 99mTc allowed precise molecular imaging ...
Esmail Jafari +3 more
doaj +1 more source
Oligometastasis in Prostate Cancer: Can We Learn from Those “Excluded” from a Phase 2 Trial?
European Urology Open Science, 2023 We conducted and previously published a phase 2 trial of metastasis-directed therapy (MDT) in men with recurrence of prostate cancer at a low prostate-specific antigen level following radical prostatectomy and postoperative radiotherapy. All patients had
Rachel M. Glicksman +6 more
doaj +1 more source
Co-Catalytic Metallopeptidases as Pharmaceutical Targets [PDF]
, 2003 Understanding the reaction mechanism of co-catalytic metallopeptidases provides a starting point for the design and synthesis of new molecules that can be screened as potential pharmaceuticals. Many of the enzymes that contain co-catalytic metallo-active
Bzymek, Krzysztof P. +2 more
core +2 more sources
Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics [PDF]
, 2019 Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR ...
Beattie, Bradley J. +10 more
core +2 more sources
Prostate specific membrane antigen (PSMA) imaging: the past is prologue
Translational Andrology and Urology, 2019 In just a few short years prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has transformed the management of prostate cancer patients. Where did this revolutionary idea come from? In this review by Rowe, Gorin and Pomper, several of the pioneers of the “PSMA revolution” provide an overview of the evolution of PSMA PET ...
Choyke, Peter L., Bouchelouche, Kirsten
openaire +2 more sources